Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CorMedix Inc.CRMD · Entity 5280 | Chief Financial Officer | August 29, 2026 | September 02, 2026 |
| MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249 | VP of Finance & CAO | October 17, 2019 | October 25, 2019 |
| Tessera Defense & Homeland Security Inc.PHGE · Entity 8384 | Director | April 14, 2025 | April 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CorMedix Inc.
Report date August 29, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 124,315 |
Reported balance
After 2026-08-29 transaction · row 1
1 source rowRow 1 · 2026-08-29 · Tax withholding · Disposed 8,424 · Balance 124,315 |
MELINTA THERAPEUTICS, INC. /NEW/
Report date October 17, 2019 · Filed October 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Melinta Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $190.00 · Expires 2026-03-21 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Shares will vest 25% on the first anniversary of the award, March 22, 2017, then ratably over the following 36 months. |
| Melinta Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $104.85 · Expires 2027-08-07 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: Shares will vest 25% on the first anniversary of the award, August 8, 2018, then ratably over the following 36 months. |
| Melinta Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $37.25 · Expires 2028-04-19 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Shares will vest 25% on the first anniversary of the award, April 18, 2019, then ratably over the following 36 months. |
| Melinta Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F4: The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to continued service with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares will vest 25% on the first anniversary of the award, March 22, 2017, then ratably over the following 36 months.
F2: Shares will vest 25% on the first anniversary of the award, August 8, 2018, then ratably over the following 36 months.
F3: Shares will vest 25% on the first anniversary of the award, April 18, 2019, then ratably over the following 36 months.
F4: The restricted stock units will vest in equal semi-annual installments over the two year period following May 16, 2019, subject to continued service with the Issuer through the applicable vesting date.
Tessera Defense & Homeland Security Inc.
Report date April 14, 2025 · Filed April 21, 2025 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Options - right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.54 · Expires 2035-04-14 | Direct | 17,600 |
Reported balance
After 2025-04-14 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2025-04-14 · Grant · Acquired 17,600 · Balance 17,600 F1: The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 29, 2026 Filed Sep 2, 2026 00:20 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 8,424 | $8.30 | $69,919.20 |
DisclosureSEC source: 0001213900-26-096386 · ownership.xml · nonDerivative · entry 1 Blum Susan · CIK 0001792253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,315 Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:31 UTC | CorMedix Inc. CRMD · Entity 5280 | Tax withholdingCommon Stock | 9,767 | $7.27 | $71,006.09 |
DisclosureSEC source: 0001213900-26-008482 · ownership.xml · nonDerivative · entry 2 Blum Susan · CIK 0001792253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,739 Read SEC document |
| January 23, 2026 Filed Jan 28, 2026 02:31 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 72,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-26-008482 · ownership.xml · nonDerivative · entry 1 Blum Susan · CIK 0001792253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,506 F1 · price: These shares represent restricted stock units granted on 01/23/2026. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. These restricted stock units vest 1/4 on the date of grant, and, subject to continued employment, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 21:09 UTC | CorMedix Inc. CRMD · Entity 5280 | GrantCommon Stock | 69,686 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-084123 · ownership.xml · nonDerivative · entry 1 Blum Susan · CIK 0001792253 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,686 F1 · price: These Restricted Stock Units were granted on 08/29/2025. Each restricted stock unit represents the right to receive one share of CorMedix Inc. common stock. The restricted stock units vest over four years in four equal installments on the first four anniversaries of the grant date, subject to continued employment through the applicable vesting date. Read SEC document |
| April 14, 2025 Filed Apr 18, 2025 20:01 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - right to Buy · Derivative | 17,600 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001213900-25-033351 · ownership.xml · derivative · entry 1 Blum Susan · CIK 0001792253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-04-14 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years. Read SEC document |
| April 14, 2025 Filed Apr 21, 2025 11:57 UTC Amendment | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - right to Buy · Derivative | 17,600 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001213900-25-033472 · ownership.xml · derivative · entry 1 Blum Susan · CIK 0001792253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-04-14 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares of common stock subject to the option vesting on April 14, 2026, and the reminder vesting in 12 equal quarterly installments over three years. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 22:48 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 264,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0001213900-24-061463 · ownership.xml · derivative · entry 1 Blum Susan · CIK 0001792253 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,000 Underlying: Common Stock · 264,000 shares Expires 2034-07-11 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on July 11, 2025, and the remainder vesting in 12 equal quarterly installments over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.